R&D channel feed

Up­dat­ed: Roche, Io­n­is launch new Hunt­ing­ton’s dis­ease study

3 years ago

Ar­row­head, Take­da liv­er drug head­ed to PhI­II de­spite place­bo re­spon­se's dent on stock

3 years ago

Arv­inas re­ports de­lay for Pfiz­er-part­nered pro­tein degra­da­tion pro­gram

3 years ago

FDA puts Ver­tex’s new Type 1 di­a­betes cell ther­a­py IND on hold; In­sil­i­co sets up for PhII of AI drug

3 years ago
News Briefing

4D Mol­e­c­u­lar paus­es en­roll­ment in Fab­ry tri­als af­ter kid­ney prob­lems in three pa­tients

3 years ago
Cell/Gene Tx

Mar­ket­ingRx roundup: Blue­bird bio pro­motes sick­le cell aware­ness; Pfiz­er, BioN­Tech en­cour­age boost­ers in South

3 years ago

Jasper scraps piv­otal plans but adds a new in­di­ca­tion as more biotechs re­vise pipelines

3 years ago
Startups

Sutro shells out lat­est up­date on ovar­i­an can­cer treat­ment, plans for piv­otal tri­al

3 years ago

Al­to touts new PhI­Ia de­pres­sion da­ta with plans to keep charg­ing for­ward

3 years ago

Day One to file NDA for pe­di­atric brain can­cer drug by sum­mer

3 years ago

Bio­Marin buffs up da­ta on he­mo­phil­ia A gene ther­a­py as FDA de­ci­sion dead­line ap­proach­es

3 years ago
Cell/Gene Tx

Up­dat­ed: Ed­i­tas ed­its pipeline, lays off 20% and says bye to CSO to kick off #JPM23 

3 years ago

Kro­nos and Genen­tech ink $20M can­cer dis­cov­ery pact

3 years ago
Deals

Bil­lion­aire-backed TCR start­up scores its first mar­quee in­dus­try al­liance

3 years ago

Doc­tors in­clined to pre­scribe new Alzheimer’s drug de­spite con­cerns

3 years ago

Break­ing: FDA clears sec­ond Alzheimer's drug in 'foun­da­tion­al spark' for field

3 years ago
Pharma
FDA+

GSK, Cure­Vac forge ahead with mid-stage plans for flu, Covid mR­NA vac­cines

3 years ago

An an­tibi­otics biotech be­gins wind-down, lays off near­ly all work­ers

3 years ago
People

Up­dat­ed: Sick­le cell gene edit­ing start­up halts tri­al af­ter flag­ging se­ri­ous side ef­fect in first pa­tient

3 years ago
Cell/Gene Tx

Pfiz­er tags ear­ly re­search pro­grams for 'ex­ter­nal­iza­tion' as it nar­rows fo­cus in rare dis­ease, can­cer

3 years ago

On­ly 1 of 25 can­cer drug de­vel­op­ers fair­ly in­clud­ed mi­nor­i­ty pa­tients over five-year win­dow, BMJ analy­sis finds

3 years ago

Af­ter an EU ap­proval, As­traZeneca and Sanofi's RSV an­ti­body seeks an FDA thumbs-up in Q3

3 years ago

Take­da touts in­ter­im PhI­II da­ta of en­zyme re­place­ment ther­a­py for rare blood dis­ease

3 years ago

Chris Viehbach­er once again sets out to re­vamp R&D at a ma­jor bio­phar­ma. The last try led to his ouster

3 years ago
People
Bioregnum
First page Previous page 103104105106107108109 Next page Last page
A service from the Financial Times